Schmitt, Christophe

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 321

Integration of in Vitro Data into Allometric Scaling to Predict Hepatic Metabolic Clearance in Man: Application to 10 Extensively Metabolized Drugs

Lave, T. H., Dupin, S., Schmitt, C., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Journal of Pharmaceutical Sciences

Pharmacogenetics and Drug MetabolismPharmaceutical studies and practices

Cited by 184

The Use of Human Hepatocytes to Select Compounds Based on Their Expected Hepatic Extraction Ratios in Humans

Lavé, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Pharmaceutical Research

Pharmacogenetics and Drug MetabolismDrug Transport and Resistance Mechanisms

Cited by 106

Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG 7697 in people with type 2 diabetes mellitus

Schmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 74

Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist RG 7697 after single subcutaneous administration in healthy subjects

Portron, A., Jadidi, S., Sarkar, N., DiMarchi, R., & Schmitt, C. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 46